Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | SVP, CFO, CBO & Treasurer | June 29, 2026 | July 01, 2026 |
| Tectonic Therapeutic, Inc.AVRO · Entity 5328 | Interim CEO, President and CFO | February 01, 2024 | February 06, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akebia Therapeutics, Inc.
Report date June 29, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 616,616 |
Reported balance
After 2026-06-29 transaction · row 1
1 source rowRow 1 · 2026-06-29 · Sale · Disposed 56,019 · Balance 616,616 F1: This sale represents an automatic "sell to cover" transaction to cover tax withholding obligations in connection with the vesting of restricted stock units granted on June 28, 2024. The sale was effected pursuant to durable automatic sell-to-cover instructions adopted by the reporting person on September 8, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale represents an automatic "sell to cover" transaction to cover tax withholding obligations in connection with the vesting of restricted stock units granted on June 28, 2024. The sale was effected pursuant to durable automatic sell-to-cover instructions adopted by the reporting person on September 8, 2025.
Tectonic Therapeutic, Inc.
Report date February 01, 2024 · Filed February 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,285 |
Ending reported balance
After 2024-02-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-02-01 · Exercise / conversion · Acquired 40,084 · Balance 42,384 Row 2 · 2024-02-05 · Tax withholding · Disposed 13,099 · Balance 29,285 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2027-02-01 | Direct | 120,249 |
Reported balance
After 2024-02-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-01 · Exercise / conversion · Disposed 40,084 · Balance 120,249 F1: The shares subject to the RSU shall vest over 4 years, with 25% vesting annually on each anniversary of the Vesting Commencement Date of February 1, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the RSU shall vest over 4 years, with 25% vesting annually on each anniversary of the Vesting Commencement Date of February 1, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 29, 2026 Filed Jul 1, 2026 20:34 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 56,019 | $1.11 | $62,181.09 |
DisclosureSEC source: 0001762507-26-000004 · primarydocument.xml · nonDerivative · entry 1 Ostrowski Erik · CIK 0001762507 · SVP, CFO, CBO & Treasurer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 616,616 F1 · shares: This sale represents an automatic "sell to cover" transaction to cover tax withholding obligations in connection with the vesting of restricted stock units granted on June 28, 2024. The sale was effected pursuant to durable automatic sell-to-cover instructions adopted by the reporting person on September 8, 2025. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:11 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 34,951 | $1.39 | $48,581.89 |
DisclosureSEC source: 0001762507-26-000002 · primarydocument.xml · nonDerivative · entry 1 Ostrowski Erik · CIK 0001762507 · SVP, CFO, CBO & Treasurer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 672,635 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025. F2 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 21:36 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 320,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001762507-26-000001 · primarydocument.xml · derivative · entry 2 Ostrowski Erik · CIK 0001762507 · SVP, CFO, CBO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,000 Underlying: Common Stock · 320,000 shares Expires 2036-01-30 F2 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 21:36 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 204,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001762507-26-000001 · primarydocument.xml · nonDerivative · entry 1 Ostrowski Erik · CIK 0001762507 · SVP, CFO, CBO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 707,586 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan, as amended. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 21:01 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 41,314 | $3.67 | $151,622.38 |
DisclosureSEC source: 0001562180-25-005201 · primarydocument.xml · nonDerivative · entry 1 Ostrowski Erik · CIK 0001762507 · SVP, CFO, CBO & Treasurer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 503,586 F1 · shares: This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 21, 2024. F2 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on June 28, 2024. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:48 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 292,300 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001562180-25-000913 · primarydocument.xml · derivative · entry 2 Ostrowski Erik · CIK 0001762507 · SVP, CFO, CBO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 292,300 Underlying: Common Stock · 292,300 shares Expires 2035-01-31 F2 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:48 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 194,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-000913 · primarydocument.xml · nonDerivative · entry 1 Ostrowski Erik · CIK 0001762507 · SVP, CFO, CBO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 544,900 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 20:31 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 500,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0001562180-24-005516 · primarydocument.xml · derivative · entry 2 Ostrowski Erik · CIK 0001762507 · SVP, CFO, CBO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2034-06-28 F2 · derivative.exercise_date: The options were granted by the Issuer as an inducement material to the Reporting Person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each vesting date. Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 20:31 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 350,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-005516 · primarydocument.xml · nonDerivative · entry 1 Ostrowski Erik · CIK 0001762507 · SVP, CFO, CBO & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,000 F1 · shares: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the RSUs will vest upon each of the first, second and third anniversaries of the grant date, subject to the Reporting Person's continued service with the Issuer on each vesting date. Read SEC document |
| February 05, 2024 Filed Feb 6, 2024 00:57 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | Tax withholdingCommon Stock | 13,099 | $1.20 | $15,745.00 |
DisclosureSEC source: 0001127602-24-003477 · form4.xml · nonDerivative · entry 2 Ostrowski Erik · CIK 0001762507 · Interim CEO, President and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,285 Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 00:57 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | Exercise / conversionRestricted Stock Unit · Derivative | 40,084 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003477 · form4.xml · derivative · entry 3 Ostrowski Erik · CIK 0001762507 · Interim CEO, President and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,249 Underlying: Common Stock · 40,084 shares Expires 2027-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the RSU shall vest over 4 years, with 25% vesting annually on each anniversary of the Vesting Commencement Date of February 1, 2023. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 00:57 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | Exercise / conversionCommon Stock | 40,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-003477 · form4.xml · nonDerivative · entry 1 Ostrowski Erik · CIK 0001762507 · Interim CEO, President and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,384 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2023 Filed Jul 3, 2023 17:17 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantRestricted Stock Unit · Derivative | 70,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-019705 · form4.xml · derivative · entry 1 Ostrowski Erik · CIK 0001762507 · Interim CEO, President and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2027-07-01 F1 · derivative.exercise_date: The shares subject to the RSU shall vest over 4 years, with 25% vesting annually on each anniversary of the Vesting Commencement Date. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 22:11 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantRestricted Stock Unit · Derivative | 160,333 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-004511 · form4.xml · derivative · entry 1 Ostrowski Erik · CIK 0001762507 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,333 Underlying: Common Stock · 160,333 shares Expires 2027-02-01 F1 · derivative.exercise_date: The shares subject to the RSU shall vest over 4 years, with 25% vesting annually on each anniversary of the Vesting Commencement Date of February 1, 2023. Read SEC document |
| December 08, 2022 Filed Dec 9, 2022 22:29 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 221,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001127602-22-027233 · form4.xml · derivative · entry 1 Ostrowski Erik · CIK 0001762507 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,000 Underlying: Common Stock · 221,000 shares Expires 2032-12-07 F1 · derivative.exercise_date: 50% of the shares shall vest and become exercisable on the first anniversary of the grant date, and the remaining 50% shall vest in equal monthly installments thereafter over a one-year period. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 22:18 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 145,000 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001127602-22-003423 · form4.xml · derivative · entry 2 Ostrowski Erik · CIK 0001762507 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: 25% of the shares shall vest and become exercisable on February 2, 2023, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 22:18 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 170,000 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001127602-22-003423 · form4.xml · derivative · entry 1 Ostrowski Erik · CIK 0001762507 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: 25% of the shares shall vest and become exercisable on February 2, 2023, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:59 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $9.63 | $0.00 |
DisclosureSEC source: 0001127602-21-019836 · form4.xml · derivative · entry 1 Ostrowski Erik · CIK 0001762507 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: 50% of the shares shall vest and become exercisable on June 10, 2023, and the remaining 50% shall vest and become exercisable on June 10, 2024. Read SEC document |
| February 04, 2021 Filed Feb 4, 2021 22:51 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 119,100 | $0.00 Strike: $16.02 | $0.00 |
DisclosureSEC source: 0001127602-21-004040 · form4.xml · derivative · entry 1 Ostrowski Erik · CIK 0001762507 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,100 Underlying: Common Stock · 119,100 shares Expires 2031-02-03 F1 · derivative.exercise_date: 25% of the shares shall vest and become exercisable on February 4, 2022, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period. Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 21:30 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 100,900 | $0.00 Strike: $21.44 | $0.00 |
DisclosureSEC source: 0001127602-20-009836 · form4.xml · derivative · entry 1 Ostrowski Erik · CIK 0001762507 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,900 Underlying: Common Stock · 100,900 shares Expires 2030-03-03 F1 · derivative.exercise_date: 25% of the shares shall vest and become exercisable on March 4, 2021, and the remaining 75% shall vest in equal monthly installments thereafter over a 3 year period. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:28 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantStock Option (Right to Buy) · Derivative | 186,000 | $0.00 Strike: $15.65 | $0.00 |
DisclosureSEC source: 0000899243-19-000539 · doc4.xml · derivative · entry 2 Ostrowski Erik · CIK 0001762507 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,000 Underlying: Common Stock · 186,000 shares Expires 2029-01-01 F2 · derivative.exercise_date: 25% of the shares vest on January 2, 2020, and the remaining 75% shall vest in equal monthly installments thereafter over a three-year period. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:28 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | GrantCommon Stock | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-000539 · doc4.xml · nonDerivative · entry 1 Ostrowski Erik · CIK 0001762507 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,300 F1 · shares: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of AVROBIO, Inc., common stock. The restricted stock units vest as follows: 25% of the shares vest on January 2, 2020, and the remaining 75% shall vest in equal monthly installments thereafter over a three-year period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.